SS Innovations to Uplist to Nasdaq
SS Innovations International (SSII) has received approval to uplist from OTC to Nasdaq Capital Market, with trading set to commence on April 25, 2025, under the same ticker 'SSII'. The company, focused on affordable surgical robotic technologies, reported significant achievements with its SSi Mantra surgical robotic system:
Key highlights include:
- Installation of 80 systems across 75 hospitals in India and other countries
- 3,500+ successful surgeries, including 195+ cardiac procedures with zero device-related complications
- First Indian company to receive CDSCO approval for telesurgery
- Completed 16 telesurgeries, including world's first robotic cardiac telesurgeries at distances up to 1,200 miles
The company reported strong financial performance with revenue of $20.6 million for 2024, a 251% increase from 2023's $5.9 million, and improved gross margin from 12.3% to 40.9%. SSII is pursuing EU CE Mark and U.S. FDA approval, expected in late 2025 and early 2026, respectively.
SS Innovations International (SSII) ha ottenuto l'approvazione per la quotazione dal mercato OTC al Nasdaq Capital Market, con l'inizio delle contrattazioni previsto per il 25 aprile 2025, mantenendo lo stesso ticker 'SSII'. L'azienda, specializzata in tecnologie robotiche chirurgiche accessibili, ha riportato importanti risultati con il suo sistema robotico chirurgico SSi Mantra:
Punti salienti includono:
- Installazione di 80 sistemi in 75 ospedali in India e altri paesi
- Oltre 3.500 interventi riusciti, inclusi più di 195 procedure cardiache senza complicazioni legate ai dispositivi
- Prima azienda indiana ad ottenere l'approvazione CDSCO per la telesurgia
- Completate 16 telesurgie, comprese le prime telesurgie cardiache robotiche al mondo a distanze fino a 1.200 miglia
L'azienda ha riportato solide performance finanziarie con un fatturato di 20,6 milioni di dollari nel 2024, un aumento del 251% rispetto ai 5,9 milioni del 2023, e un miglioramento del margine lordo dal 12,3% al 40,9%. SSII sta perseguendo la certificazione CE per l'UE e l'approvazione FDA negli USA, previste rispettivamente per fine 2025 e inizio 2026.
SS Innovations International (SSII) ha recibido la aprobación para pasar de OTC al Nasdaq Capital Market, con inicio de operaciones previsto para el 25 de abril de 2025, manteniendo el mismo símbolo bursátil 'SSII'. La compañía, enfocada en tecnologías robóticas quirúrgicas asequibles, reportó logros significativos con su sistema quirúrgico robótico SSi Mantra:
Aspectos destacados incluyen:
- Instalación de 80 sistemas en 75 hospitales en India y otros países
- Más de 3,500 cirugías exitosas, incluyendo más de 195 procedimientos cardíacos sin complicaciones relacionadas con el dispositivo
- Primera empresa india en recibir aprobación CDSCO para telescirugía
- Completadas 16 telescirugías, incluyendo las primeras telescirugías cardíacas robóticas del mundo a distancias de hasta 1,200 millas
La compañía reportó un sólido desempeño financiero con ingresos de 20.6 millones de dólares en 2024, un aumento del 251% respecto a los 5.9 millones de 2023, y una mejora en el margen bruto del 12.3% al 40.9%. SSII está en proceso de obtener la marca CE de la UE y la aprobación de la FDA de EE.UU., esperadas para finales de 2025 y principios de 2026, respectivamente.
SS Innovations International (SSII)는 OTC 시장에서 나스닥 캐피털 마켓으로 상장 승인을 받았으며, 2025년 4월 25일부터 동일한 티커 'SSII'로 거래가 시작될 예정입니다. 저렴한 수술용 로봇 기술에 주력하는 이 회사는 SSi Mantra 수술용 로봇 시스템으로 다음과 같은 중요한 성과를 보고했습니다:
주요 내용은 다음과 같습니다:
- 인도 및 기타 국가의 75개 병원에 80대 시스템 설치
- 3,500건 이상의 성공적인 수술, 그 중 195건 이상의 심장 수술에서 장치 관련 합병증 없음
- 텔레서저리(CDSCO) 승인을 받은 최초의 인도 기업
- 최대 1,200마일 거리에서 세계 최초의 로봇 심장 텔레서저리를 포함한 16건의 텔레서저리 완료
회사는 2024년 매출 2,060만 달러를 기록하며 2023년 590만 달러 대비 251% 증가했고, 총이익률은 12.3%에서 40.9%로 개선되었습니다. SSII는 2025년 말과 2026년 초에 각각 EU CE 인증과 미국 FDA 승인을 목표로 하고 있습니다.
SS Innovations International (SSII) a obtenu l'approbation pour passer du marché OTC au Nasdaq Capital Market, avec un début de cotation prévu le 25 avril 2025 sous le même symbole boursier 'SSII'. L'entreprise, spécialisée dans les technologies robotiques chirurgicales abordables, a annoncé des réalisations majeures avec son système robotique chirurgical SSi Mantra :
Points clés :
- Installation de 80 systèmes dans 75 hôpitaux en Inde et dans d'autres pays
- Plus de 3 500 interventions réussies, dont plus de 195 interventions cardiaques sans complications liées aux dispositifs
- Première entreprise indienne à obtenir l'approbation CDSCO pour la téléchirurgie
- Réalisation de 16 téléchirurgies, y compris les premières téléchirurgies cardiaques robotiques au monde à des distances allant jusqu'à 1 200 miles
L'entreprise a affiché de solides performances financières avec un chiffre d'affaires de 20,6 millions de dollars en 2024, soit une augmentation de 251 % par rapport aux 5,9 millions de 2023, et une amélioration de la marge brute de 12,3 % à 40,9 %. SSII poursuit l'obtention du marquage CE pour l'UE et de l'approbation FDA aux États-Unis, attendues respectivement fin 2025 et début 2026.
SS Innovations International (SSII) hat die Genehmigung erhalten, vom OTC-Markt auf den Nasdaq Capital Market zu wechseln, wobei der Handel am 25. April 2025 unter dem gleichen Ticker 'SSII' beginnen soll. Das Unternehmen, das sich auf erschwingliche chirurgische Robotertechnologien konzentriert, meldete bedeutende Erfolge mit seinem SSi Mantra chirurgischen Robotersystem:
Wichtige Highlights umfassen:
- Installation von 80 Systemen in 75 Krankenhäusern in Indien und anderen Ländern
- Über 3.500 erfolgreiche Operationen, darunter mehr als 195 Herzoperationen ohne gerätebedingte Komplikationen
- Erstes indisches Unternehmen mit CDSCO-Zulassung für Telesurgery
- Abschluss von 16 Telesurgeries, darunter die weltweit ersten robotergestützten Herz-Telesurgeries über Entfernungen von bis zu 1.200 Meilen
Das Unternehmen berichtete über starke finanzielle Leistungen mit einem Umsatz von 20,6 Millionen US-Dollar für 2024, eine Steigerung von 251 % gegenüber 5,9 Millionen im Jahr 2023, sowie einer Verbesserung der Bruttomarge von 12,3 % auf 40,9 %. SSII strebt die EU-CE-Kennzeichnung und die US-FDA-Zulassung an, die voraussichtlich Ende 2025 bzw. Anfang 2026 erfolgen sollen.
- Revenue grew 251% to $20.6 million in 2024
- Gross margin improved significantly from 12.3% to 40.9%
- Successfully installed 80 SSi Mantra systems across 75 hospitals
- Completed 3,500+ surgeries with zero device-related complications
- Uplisting to Nasdaq expected to improve trading liquidity
- None.
FORT LAUDERDALE, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s common stock has been approved for listing on The Nasdaq Capital Market® (“Nasdaq”). Trading on Nasdaq is expected to commence on April 25, 2025, and the Company’s shares will continue to be listed under the ticker symbol “SSII”.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Uplisting to Nasdaq marks an exciting milestone for SS Innovations and reflects our team’s achievements in building a world-class robotic surgery technology platform that is designed to offer top-tier quality, safety, efficiency and affordability, enabling cutting-edge robotic surgical procedures for a wider range of patients globally.
“The timing of our uplisting coincides with the beginning of our global expansion beyond India – into Nepal, Ecuador, Guatemala, the Philippines, Indonesia, Sri Lanka and Ukraine – and our planned strategic entry into Europe and the United States. We are pursuing EU CE Mark and U.S. FDA approval for our SSi Mantra surgical robotic system, which we anticipate in late 2025 and early 2026, respectively. We believe that the Nasdaq uplisting will enhance market awareness of our growth story, improve transparency, expand our audience of potential investors, and ultimately increase share liquidity.”
Dr. Srivastava also highlighted the Company’s recent achievements in advancing its clinically validated, patented surgical robotic system, the “SSi Mantra,” including:
- Installing 80 SSi Mantra systems in 75 hospitals across India and other countries;
- 3,500+ surgeries performed using the SSi Mantra, including over 195 robotic cardiac surgeries with zero reported device-related mortality, injuries, or complications;
- Becoming the first and only company in India to receive Central Drugs Standard Control Organization (CDSCO, India’s equivalent of the U.S. FDA) regulatory approval for use of a robotic surgical system in the performance of telesurgery and tele-proctoring procedures. Since receiving such approvals, the Company has performed 16 telesurgeries using SSi Mantra, including the world’s first robotic cardiac telesurgeries over distances up to 1,200 miles; and
- Reporting revenue for the year ended December 31, 2024 of
$20.6 million , an approximately251% increase from 2023 revenue of$5.9 million , and gross margin of40.9% , an increase from12.3% in 2023.
About SS Innovations
SS Innovations International, Inc. (OTC: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
About the SSi Mantra
The SSi Mantra Surgical Robotic System is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward-Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations International’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@equityny.com
Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@equityny.com
Media Contact:
press@ssinnovations.org
T: (212) 739-0300
FAQ
When will SS Innovations (SSII) start trading on Nasdaq?
What was SS Innovations (SSII) revenue growth in 2024?
How many surgeries have been performed using SSi Mantra robotic system?
When does SS Innovations expect FDA and CE Mark approval for SSi Mantra?
What is SS Innovations' achievement in telesurgery?
